Imugene doses first patient in “hard to treat” cancer drug trial
Fresh from news of a “complete response” from other clinical trials last week, Imugene (ASX: IMU) has now dosed the first patient with a...
top of page
Search
Doug Bright
Nov 8
Imugene launches first Aussie lymphoma cancer trial
In an Australian first, clinical cancer researcher and developer Imugene (ASX: IMU) will launch its first “azer-cel” clinical trial...
Doug Bright
Nov 5
Imugene hails 2-year “complete response” in cancer trial
Clinical-stage immuno-oncology company Imugene (ASX: IMU) is celebrating more than two years’ “complete response” for one of its bile...
Craig Nolan
Sep 18
Imugene gets crucial FDA nod for bile tract cancer drug
Imugene (ASX: IMU) has landed a prized United States Food and Drug Administration (FDA) orphan drug approval for its bile tract cancer...
Andrew Todd
Sep 2
Early trial results leave Imugene patients cancer-free
The first two blood cancer patients taking part in a United States-based trial, who had suffered relapses despite having treatment, have...
Craig Nolan
Jul 10
Imugene delivers first Aussie bile tract cancer trial dose
Imugene (ASX: IMU) has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract...
Doug Bright
Jun 24
Imugene delivers first combo dose in bile tract cancer study
Imugene (ASX: IMU) has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the...
Helen Barling
Apr 16
Imugene cancer fight bolstered by strategic US partnership
Australian anti-cancer company Imugene (ASX: IMU) has stamped a strategic manufacturing and processing agreement with Kincell Bio, with...
Steve Butler
Apr 15
Imugene launches pivotal bile tract cancer expansion study
ASX-listed medical technology company Imugene (ASX: IMU) has launched a pivotal expansion study targeting patients with bile tract...
Michael Philipps
Apr 4
Imugene locks down cancer patent in massive Chinese market
Australian anti-cancer company Imugene (ASX: IMU) has received a patent to protect its unique cancer treatment in China – the largest and...
Michael Philipps
Mar 11
Imugene to tackle cancer tumours with combo treatment
Imugene (ASX: IMU) has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for...
Michael Philipps
Feb 15
Imugene advances search-and-destroy cancer mission
An Australian-based medical mission to flesh out and kill cancerous cells in humans has received a boost after ASX-listed medtech Imugene...
Doug Bright
Jan 19
Imugene extends anti-cancer trial following recent successes
Following recent successes, Imugene has advanced its Phase 1 clinical study with the first Cohort 5 patients now receiving doses of the...
Doug Bright
Jan 17
Imugene to expand cancer treatment trial following early success
Clinical stage immune-oncology company Imugene has reported some eye-catching results in an update of its Phase 1 trial to assess the...
Doug Bright
Dec 12, 2023
Imugene out to supercharge cancer patients in new alliance
Imugene has joined with United States-based NeoImmuneTech (NIT) for a two-year collaboration aimed at combining their respective...
Michael Philipps
Dec 6, 2023
Imugene on brink of European patent for cancer drug
Imugene expects to secure a crucial patent for its “PD1-Vaxx” lung cancer vaccine from the European Patent Office this month, with a...
Doug Bright
Nov 28, 2023
Imugene cancer virus earns crucial FDA fast-track status
The US Food and Drug Administration has stamped Imugene’s “Vaxinia” drug trials aimed at treating bile duct cancer with “fast-track”...
Michael Philipps
Nov 13, 2023
Cancer-fighting mission shoots Imugene up ASX boards
Cancer. In modern days of fast vehicles and seemingly even faster living, there are few people or families who have not been touched by...
Doug Bright
Nov 10, 2023
Holy grail cancer treatment one step closer for Imugene
Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient...
Helen Barling
Nov 6, 2023
Hope grows with positive signals in Imugene cancer trial
Australian immune-oncology company Imugene has recorded positive early signals from the first phase of its metastatic advanced solid...
bottom of page